204 related articles for article (PubMed ID: 23789604)
1. Adjuvant rituximab in the treatment of pemphigus vulgaris: a phase II clinical trial.
Balighi K; Daneshpazhooh M; Khezri S; Mahdavi-nia M; Hajiseyed-javadi M; Chams-Davatchi C
Int J Dermatol; 2013 Jul; 52(7):862-7. PubMed ID: 23789604
[TBL] [Abstract][Full Text] [Related]
2. Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients.
Kim MR; Kim HC; Kim SC
Dermatology; 2011; 223(2):182-8. PubMed ID: 22025028
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of rituximab in pemphigus: experience of the German Registry of Autoimmune Diseases.
Kasperkiewicz M; Eming R; Behzad M; Hunzelmann N; Meurer M; Schulze-Koops H; von Wussow P; Hertl M; Zillikens D; Freivogel K; Dörner T; Schmidt E
J Dtsch Dermatol Ges; 2012 Oct; 10(10):727-32. PubMed ID: 22577946
[TBL] [Abstract][Full Text] [Related]
4. Childhood pemphigus vulgaris successfully treated with rituximab.
Kanwar AJ; Sawatkar GU; Vinay K; Hashimoto T
Indian J Dermatol Venereol Leprol; 2012; 78(5):632-4. PubMed ID: 22960821
[TBL] [Abstract][Full Text] [Related]
5. Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients.
Matsukura S; Knowles SR; Walsh S; Shear NH
Arch Dermatol; 2012 Jun; 148(6):734-9. PubMed ID: 22351790
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris.
Behzad M; Möbs C; Kneisel A; Möller M; Hoyer J; Hertl M; Eming R
Br J Dermatol; 2012 Apr; 166(4):844-52. PubMed ID: 22092243
[TBL] [Abstract][Full Text] [Related]
7. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).
Marzano AV; Fanoni D; Venegoni L; Berti E; Caputo R
Dermatology; 2007; 214(4):310-8. PubMed ID: 17460402
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of rituximab treatment in Indian pemphigus patients.
Kanwar AJ; Tsuruta D; Vinay K; Koga H; Ishii N; Dainichi T; Hashimoto T
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e17-23. PubMed ID: 22176540
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.
Uzun S; Bilgiç Temel A; Akman Karakaş A; Ergün E; Özkesici B; Eskiocak AH; Erat A; Uğurlu N; Nazlım B; Koç S; Bozkurt S; Dicle Ö; Alpsoy E; Yılmaz E
Int J Dermatol; 2016 Dec; 55(12):1362-1368. PubMed ID: 27653507
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients.
Kasperkiewicz M; Shimanovich I; Ludwig RJ; Rose C; Zillikens D; Schmidt E
J Am Acad Dermatol; 2011 Sep; 65(3):552-558. PubMed ID: 21641080
[TBL] [Abstract][Full Text] [Related]
11. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up.
Cianchini G; Lupi F; Masini C; Corona R; Puddu P; De Pità O
J Am Acad Dermatol; 2012 Oct; 67(4):617-22. PubMed ID: 22243765
[TBL] [Abstract][Full Text] [Related]
12. Recalcitrant pemphigus vulgaris: aseptic meningitis associated with intravenous immunoglobulin therapy and successful treatment with rituximab.
Ventura F; Rocha J; Fernandes JC; Machado A; Brito C
Int J Dermatol; 2013 Apr; 52(4):501-2. PubMed ID: 23451774
[No Abstract] [Full Text] [Related]
13. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris.
Faurschou A; Gniadecki R
Int J Dermatol; 2008 Mar; 47(3):292-4. PubMed ID: 18289336
[TBL] [Abstract][Full Text] [Related]
14. Durable remission of pemphigus with a fixed-dose rituximab protocol.
Heelan K; Al-Mohammedi F; Smith MJ; Knowles S; Lansang P; Walsh S; Shear NH
JAMA Dermatol; 2014 Jul; 150(7):703-8. PubMed ID: 24500264
[TBL] [Abstract][Full Text] [Related]
15. Intralesional Rituximab in the Treatment of Refractory Oral Pemphigus Vulgaris.
Vinay K; Kanwar AJ; Mittal A; Dogra S; Minz RW; Hashimoto T
JAMA Dermatol; 2015 Aug; 151(8):878-82. PubMed ID: 25536513
[TBL] [Abstract][Full Text] [Related]
16. Low-dose rituximab is effective in pemphigus.
Horváth B; Huizinga J; Pas HH; Mulder AB; Jonkman MF
Br J Dermatol; 2012 Feb; 166(2):405-12. PubMed ID: 21967609
[TBL] [Abstract][Full Text] [Related]
17. [Effectiveness and safety of rituximab in pemphigus vulgaris].
Alonso Sánchez A; García Rodríguez S; López Avila A; Rabell Iñigo S
Farm Hosp; 2010; 34(2):98-9. PubMed ID: 20304370
[No Abstract] [Full Text] [Related]
18. Rituximab therapy in severe juvenile pemphigus vulgaris.
Mamelak AJ; Eid MP; Cohen BA; Anhalt GJ
Cutis; 2007 Oct; 80(4):335-40. PubMed ID: 18038698
[TBL] [Abstract][Full Text] [Related]
19. Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus.
Londhe PJ; Kalyanpad Y; Khopkar US
Indian J Dermatol Venereol Leprol; 2014; 80(4):300-5. PubMed ID: 25035353
[TBL] [Abstract][Full Text] [Related]
20. Is it time to re-evaluate the treatment of pemphigus?
Leventhal JS; Sanchez MR
J Drugs Dermatol; 2012 Oct; 11(10):1200-6. PubMed ID: 23134985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
